(Note: This is a SPAC or blank-check IPO consisting of Class A ordinary shares – and NOT units. The typical SPAC or blank-check IPO is a unit offering of stock and warrants to buy stock. Up to 5 percent of the stock in this offering was made available to retail investors by underwriter SoFi Securities on its online trading platform, SoFi, the prospectus says.)

This is the fourth new biotech-focused blank-check company or SPAC created by the partnership of Chamath Palihapitiya, the founder and current Managing Partner of Social Capital, and Kishan (a/k/a Kishen) Mehta, the Portfolio Manager of the Averill strategy at Suvretta. Mr Palihapitiya is the chairman and the CEO of this SPAC, along with the other three SPACs under the Social Capital Suvretta name. Mr. Mehta is the president and a director of all four Social Capital Suvretta SPACs. (Incorporated in the  Cayman Islands) 

We intend to focus our search for a target business operating in the biotechnology industry and within the immunology subsector.

(Note: Social Capital Suvretta Holdings Corp. IV upsized its SPAC IPO on June 29, 2021, at pricing to 22 million Class A ordinary shares, up from 20 million shares in the prospectus, at $10 each to raise $220 million.)